-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
High-grade gliomas account for 8%-10% of children's brain tumors.
Childhood Immunization
Recently, researchers conducted a phase I clinical study to evaluate the efficacy and safety of G207 oncolytic virus therapy.
Recently, researchers conducted a phase I clinical study to evaluate the efficacy and safety of G207 oncolytic virus therapy.
The study adopted a 3+3 design, and biopsy confirmed the participation of children with recurrent or progressive supratentorial brain tumors.
Twelve patients with high-grade glioma received G207 treatment, ranging in age from 7 to 18 years old.
11 patients had imaging, neuropathology or clinical remission, and the average overall survival time of the patients was 12.
Studies have found that intratumoral injection of G207 or combined radiotherapy can significantly alleviate the condition of relapsed or progressive high-grade gliomas in children, and it is well tolerated .
Intratumoral injection of G207 or combined radiotherapy can significantly alleviate the condition of patients with recurrent or progressive high-grade glioma in children, and is well tolerated.
Original source:
Gregory K.
Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.
Leave a message here